Pardes Biosciences (NASDAQ:PRDS – Get Rating) had its price objective dropped by investment analysts at SVB Leerink from $12.00 to $9.00 in a research report issued on Friday, Benzinga reports. The firm currently has an "outperform" rating on the stock. SVB Leerink's target price indicates a potential upside of 426.32% from the company's previous close.
Separately, JMP Securities began coverage on Pardes Biosciences in a research note on Tuesday, December 13th. They set a "market outperform" rating and a $9.00 price target for the company.
Get Pardes Biosciences alerts:Pardes Biosciences Price Performance
Pardes Biosciences stock opened at $1.71 on Friday. Pardes Biosciences has a one year low of $0.75 and a one year high of $13.01. The business has a fifty day moving average of $1.45 and a two-hundred day moving average of $2.06.
Pardes Biosciences (NASDAQ:PRDS – Get Rating) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.09. On average, analysts expect that Pardes Biosciences will post -1.77 earnings per share for the current fiscal year.Institutional Trading of Pardes Biosciences
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp purchased a new stake in Pardes Biosciences in the 1st quarter valued at about $75,000. American International Group Inc. acquired a new position in Pardes Biosciences during the 2nd quarter worth approximately $41,000. Virtu Financial LLC acquired a new position in Pardes Biosciences during the 3rd quarter worth approximately $25,000. Dynamic Technology Lab Private Ltd acquired a new position in Pardes Biosciences during the 1st quarter worth approximately $105,000. Finally, JPMorgan Chase & Co. acquired a new position in Pardes Biosciences during the 2nd quarter worth approximately $47,000.
About Pardes Biosciences
(Get Rating)
Pardes Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases.
Read More
- Get a free copy of the StockNews.com research report on Pardes Biosciences (PRDS)
- EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
- Does Oil Services Firm NOV Have Enough Energy To Maintain Rally?
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
Receive News & Ratings for Pardes Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pardes Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.